Cancer Drugs Market by Type (Bladder Cancer, Blood Cancer, Breast Cancer), Application (Chemotherapy, Hormone Therapy, Immunotherapy) - Global Forecast 2023-2030

Cancer Drugs Market by Type (Bladder Cancer, Blood Cancer, Breast Cancer), Application (Chemotherapy, Hormone Therapy, Immunotherapy) - Global Forecast 2023-2030

The Cancer Drugs Market is projected to reach USD 158.59 billion by 2030 from USD 73.03 billion in 2022, at a CAGR of 10.17% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Cancer Drugs Market.
  • Based on Type, market is studied across Bladder Cancer, Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Liver Cancer, Lung and Bronchus Cancer, and Skin Cancer. The Bladder Cancer is projected to witness significant market share during forecast period.
  • Based on Application, market is studied across Chemotherapy, Hormone Therapy, Immunotherapy, and Targeted Therapy. The Chemotherapy is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Cancer Drugs Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Cancer Drugs Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GSK PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Company Limited.

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Cancer Drugs Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Cancer Drugs Market?
  3. What is the competitive strategic window for identifying opportunities in the Cancer Drugs Market?
  4. What are the latest technology trends and regulatory frameworks in the Cancer Drugs Market?
  5. What is the market share of the leading vendors in the Cancer Drugs Market?
  6. Which modes and strategic moves are suitable for entering the Cancer Drugs Market?

Note: PDF & Excel + Online Access - 1 Year

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers Prevalence of cancer across the globe and surge in global geriatric population Increase in government expenditures on healthcare Elevated development of biosimilar in oncology arena
5.1.2. Restraints High cost and lack of availability of the drug
5.1.3. Opportunities Increase in number of pipeline drugs Growing R&D for development of effient cancer drugs
5.1.4. Challenges Adverse effects associated with the use of cancer drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Cancer Drugs Market, by Type
6.1. Introduction
6.2. Bladder Cancer
6.3. Blood Cancer
6.4. Breast Cancer
6.5. Gastrointestinal Cancer
6.6. Liver Cancer
6.7. Lung and Bronchus Cancer
6.8. Skin Cancer
7. Cancer Drugs Market, by Application
7.1. Introduction
7.2. Chemotherapy
7.3. Hormone Therapy
7.4. Immunotherapy
7.5. Targeted Therapy
8. Americas Cancer Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Cancer Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Cancer Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AbbVie Inc.
12.1.2. Amgen Inc.
12.1.3. Astellas Pharma Inc.
12.1.4. AstraZeneca PLC
12.1.5. Bayer AG
12.1.6. Bristol-Myers Squibb Company
12.1.7. Eli Lilly and Company
12.1.8. Gilead Sciences, Inc.
12.1.9. GSK PLC
12.1.10. Johnson & Johnson
12.1.11. Merck & Co., Inc.
12.1.12. Novartis AG
12.1.13. Pfizer Inc.
12.1.14. Sanofi SA
12.1.15. Takeda Pharmaceutical Company Limited
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings